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o the Editor,
e  read with great interest the article by Carmen Sánchez-
erales et al., recently published in Nefrología.1 In this study,
he authors analysed the presence of valvular calciﬁcation in
atients starting dialysis and its relationship to cardiovascular
vents and cardiovascular death. We would like to offer some
omments on the study.
Valvular calciﬁcation may occur in the presence or absence
f renal disease. In individuals without renal disease, calciﬁ-
ation is usually a result of a pro-inﬂammatory state caused
y other comorbidities such as diabetes, dyslipidaemia, and
ypertension. In individuals with chronic kidney disease
CKD), often it cannot be established with certainty whether
alciﬁcation is due to changes in bone mineral metabolism,
nﬂammation caused by comorbidities, or both.2
In the “methods” section of the study, the authors stated
hat they measured serum levels of phosphorus, calcium, and
arathyroid hormone (PTH). However, calcium and PTH were
ot included in the univariate analysis. We  think that the
tatistical analysis of these two variables would be relevant,
ecause the studies performed by Streja et al.3 and Floege
t al.,4 found that patients with serum values of intact PTH,
alcium, and phosphate outside the ranges recommended by
he Kidney Disease Outcomes Quality Initiative (KDOQITM)5
iPTH, 150–300 pg/mL; calcium, 2.10–2.37 mmol/L; and phos-
hate, 1.13–1.78 mmol/L) had a higher mortality risk than
atients with values within these ranges.
In the multivariate analysis by Sánchez-Perales et al.,
he authors state that the model was adjusted for factors
ith statistical signiﬁcance in the univariate analysis and for
ther factors that were potentially involved in the valvular
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5calciﬁcation process. However, it was not clear why variables
associated with valvular calciﬁcation in patients with CKD
(PTH, calcium, and phosphate) were not included.
Finally, whilst the study demonstrates that the presence
of valvular calciﬁcation is a predictor of mortality, the anal-
ysis performed does not establish whether calciﬁcation is
secondary to atherogenic comorbidities or to an imbalance
of bone mineral metabolism. Future studies could further
explore this association.
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Lots  of steroids  and vitamins,  tons  of complications.
Hypercalcemia and  nephrocalcinosis  as important
complications of  performance-enhancing  drugs
Montones  de  esteroides  y  vitaminas,  toneladas  de  complicaciones.
Hipercalcemia  y  nefrocalcinosis  como  complicaciones  importantes
de  los  fármacos  para  mejorar  el  rendimiento
Dear Editor,
Chronic hypercalcemia can be an important complica-
tion of anabolic steroid and vitamin supplement abuse.
We report the case of a 30-year-old bodybuilder that for
more  than 4 years used injectable anabolic-androgenic
steroids (AAS) and one veterinary polyvitamin formulation
with vitamin A (2,100,000 IU), D (ergocalciferol: 60,000 IU),
and E (55 IU) on a monthly basis. He also reported self-
injecting mineral oil intramuscularly for esthetic purposes
for more  than 2 years. He presented to the emergency
room with an acute, severe epigastric pain, associated
with nausea and vomiting. Laboratory evaluation (Table 1)
demonstrated an elevated amylase 2500 IU/L (50–160 IU/L);
lipase of 612 IU/L (0–75 IU/L); a corrected serum calcium of
12.5 mg/dL (8.5–10.5 mg/dL); PTH of 73.2 pg/mL (15–68.3 pg/mL)
and 25(OH)D of 65.1 ng/mL (30–100 ng/mL). Serum creatinine
was 1.2 mg/dL (0.6–1.2 mg/dL). Abdominal ultrasound showed
a diffusely edematous pancreas, bilateral ureterolithiasis and
nephrocalcinosis. A high-resolution CT of the chest and
abdomen was performed and revealed absence of granulomas
and lymphadenopathies. He had a tormented clinical course,
with acute kidney injury (attributed to volume depletion
and renal vasoconstriction in the setting of hypercalcemia)
without the need of hemodialysis; protracted vomiting that
lead to a laparoscopic duodenum–jejunum anastomosis with
improvement of complains and multiple infectious compli-
cations. Serum calcium and PTH returned to normal levels
(9 mg/dL and 35 pg/mL, respectively) after vitamin D discon-
tinuation, vigorous venous hydration with 0.9% saline infusion
and therapy with furosemide and corticosteroids. After more
With the desire to improve performance, some athletes or
amateurs use performance-enhancing drugs. The widespread
use of these substances without medical prescription or clini-
cal follow-up can lead to serious health problems as described
on several reports.1–3 We believe that the main clinical fea-
tures seen in this patient are due to chronic hypercalcemia due
to multiple substance abuse and parafﬁnomas. The associa-
tion between focal segmental glomerulosclerosis and anabolic
steroids abuse may be explained by increase in lean body
mass and potential direct nephrotoxic effects of anabolic
steroids.1 Furthermore, this drug modulates steroid hydroxy-
lase activity predisposing to hypercalcemia.4 The association
of vitamin A toxicity and hypercalcemia is rare but well rec-
ognized. It is attributed to a direct effect on bone (activation
of bone reabsorption with increased osteoclast activity),5 on
the parathyroid, or in both.6 According to Chertow et al.,
vitamin A stimulate PTH secretion in bovine parathyroid
tissue and in men.6,7 The minimum dose of vitamin A
required to produce hypercalcemia cannot be stated with cer-
tainty; toxicity has been described from doses ranging from
50,000 to 500,000 IU/day.5 Although we did not measure the
value of vitamin A in blood, the patient injected more  than
2,100,000 IU/month (which correspond 70.000 IU of vitamin
A/day) for more  than 4 years, which is compatible with toxicity.
Hypercalcemia is a well-known but uncommon complication
of vitamin D intake.8 Usually results from doses that exceed
10,000 IU/day, and is generally associated with serum lev-
els of 25-hydroxyvitamin D that are well above 150 ng/mL.8
In this case, 60,000 IU of ergocalciferol were inject monthly
and serum vitamin D was in the upper limit of normal.
The tolerable upper level of daily vitamin D intake recentlythan 60 days of hospitalization he was discharged home hav-
ing made a full recovery.set by the Institute of Medicine is 4000 IU.8 Vitamin A and
D can act synergistically to cause hypercalcemia. Contrary
